(IPCI) MC $39 M // 8 Drugs awaiting FDA approval + 2x Blockbusters ready for P3 = 1000% Potential !!!
FDA approval for Focalin XR expected for this Quarter...GL
This Low float Stock awaiting 8 FDA approvals and has another 2 Potential Blockbusters ready for Phase 3
Foclian XR alone which is Partnered with Par Pharma will drive IPCI deep into Profitability quickly after Market Launch .There is NO generic version of Focalin XR available on the Market , IPCI & Par will be the first here and its normal that the first generic takes 30%-40% of market share quickly after launch .
5-6 FDA approvals expcted within 12 months .This Gem has everything to move into Double Digits the Market Cap of $40 Million is a Big Joke .
Market Cap:$ 39 M
Cash : $3 M
Shares Out: 21 Mil..(10 Mil Shares held by Insiders/Institutions)
Low Float: 11 M
8 Generic Drug Applications Filed with the FDA
We currently have eight Abbreviated New Drug Applications awaiting FDA approval. These include generics of Focalin XR® Effexor XR®, Protonix ®' Glucophage ® XR,Seroquel XR®, Lamictaf® XR Keppra XR® and Pristiq® .Together, these products represent approximately $4.78 of branded and generic sales.
Our lead product, a generic version of Focal in XR®, is partnered with Par Pharmaceuticals Inc., a top ten U.S.pharmaceutical company.As a result of a settlement with the innovator company, we expect to marketing of our generic versions ofFocalin XR® upon approval. We have a ten year profit-sharing agreement with Par for the sale of a generic version of Focal in XR® in the U.S.,which commences with the commercial launch of the product by Par .